These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11166014)

  • 1. Human kallikrein 6 as a biomarker of alzheimer's disease.
    Diamandis EP; Yousef GM; Petraki C; Soosaipillai AR
    Clin Biochem; 2000 Nov; 33(8):663-7. PubMed ID: 11166014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered kallikrein 7 and 10 concentrations in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
    Diamandis EP; Scorilas A; Kishi T; Blennow K; Luo LY; Soosaipillai A; Rademaker AW; Sjogren M
    Clin Biochem; 2004 Mar; 37(3):230-7. PubMed ID: 14972646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications.
    Diamandis EP; Yousef GM; Soosaipillai AR; Grass L; Porter A; Little S; Sotiropoulou G
    Clin Biochem; 2000 Jul; 33(5):369-75. PubMed ID: 11018688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients.
    Zarghooni M; Soosaipillai A; Grass L; Scorilas A; Mirazimi N; Diamandis EP
    Clin Biochem; 2002 May; 35(3):225-31. PubMed ID: 12074831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues.
    Luo LY; Grass L; Howarth DJ; Thibault P; Ong H; Diamandis EP
    Clin Chem; 2001 Feb; 47(2):237-46. PubMed ID: 11159772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma.
    Diamandis EP; Yousef GM; Soosaipillai AR; Bunting P
    Clin Biochem; 2000 Oct; 33(7):579-83. PubMed ID: 11124344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin.
    Hutchinson S; Luo LY; Yousef GM; Soosaipillai A; Diamandis EP
    Clin Chem; 2003 May; 49(5):746-51. PubMed ID: 12709365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.
    Menendez-Gonzalez M; Castro-Santos P; Suarez A; Calatayud MT; Perez-Pinera P; Martinez M; Ribacoba R; Gutierrez C
    J Alzheimers Dis; 2008 May; 14(1):59-67. PubMed ID: 18525128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human kallikreins 6 and 10 in ascites fluid from ovarian cancer patients.
    Luo LY; Soosaipillai A; Grass L; Diamandis EP
    Tumour Biol; 2006; 27(5):227-34. PubMed ID: 16864975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
    Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
    J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
    Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
    Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Giau VV; Bagyinszky E; Lim KT; Kang SM; An SS; Park YH; Youn YC; Kim S
    J Alzheimers Dis; 2016 May; 52(4):1403-13. PubMed ID: 27163824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors.
    Magklara A; Mellati AA; Wasney GA; Little SP; Sotiropoulou G; Becker GW; Diamandis EP
    Biochem Biophys Res Commun; 2003 Aug; 307(4):948-55. PubMed ID: 12878203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.
    Somers C; Goossens J; Engelborghs S; Bjerke M
    Biomark Med; 2017 Feb; 11(2):169-178. PubMed ID: 28111962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
    Engelborghs S
    Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.